Laneta Dorflinger, PhD, is distinguished scientist and vice president at FHI 360 (formerly known as Family Health International). She is a technical leader for contraceptive technology development and introduction activities, including initiatives on several long-acting contraceptive approaches. She directs the Preventive Technologies Agreement, a global program to characterize safety and effectiveness of microbicides and oral pre-exposure prophylaxis (PrEP), expand understanding of the interface between technology and behavior, and improve service delivery models for integration of family planning and HIV. Before joining FHI, Dr. Dorflinger consulted on developing strategies on the introduction of Norplant contraceptive implants into developing world programs and served for seven years as a biomedical scientist in the Office of Population at USAID. In this role, she focused on the development, introduction, and post-marketing assessments of contraceptive technology and traveled extensively in the developing world. Dr. Dorflinger has received several noteworthy awards, including the Science and Technology in Development award from USAID. She has also served on a number of committees, including the WHO task force on long-acting systemic methods of fertility regulation and the Institute of Medicine’s committee on oral contraceptives and breast cancer. She has authored or coauthored numerous articles on contraceptive technology and microbicides. She received her undergraduate degree in chemistry from Lafayette College and her PhD in physiology from Yale University. She did post-doctoral training at the Harvard School of Public Health.